For: | Konda B, Shum H, Rajdev L. Anti-angiogenic agents in metastatic colorectal cancer. World J Gastrointest Oncol 2015; 7(7): 71-86 [PMID: 26191351 DOI: 10.4251/wjgo.v7.i7.71] |
---|---|
URL: | https://www.wjgnet.com/1948-5204/full/v7/i7/71.htm |
Number | Citing Articles |
1 |
Eglal Mahgoub, Jalal Taneera, Nabil Sulaiman, Maha Saber-Ayad. The role of autophagy in colorectal cancer: Impact on pathogenesis and implications in therapy. Frontiers in Medicine 2022; 9 doi: 10.3389/fmed.2022.959348
|
2 |
Ozkan Kanat, Hulya Ertas. Existing anti-angiogenic therapeutic strategies for patients with metastatic colorectal cancer progressing following first-line bevacizumab-based therapy. World Journal of Clinical Oncology 2019; 10(2): 52-61 doi: 10.5306/wjco.v10.i2.52
|
3 |
Jin Wang, Xiaomu Zhao, Lan Jin, Guocong Wu, Yingchi Yang. UBR5 Contributes to Colorectal Cancer Progression by Destabilizing the Tumor Suppressor ECRG4. Digestive Diseases and Sciences 2017; 62(10): 2781 doi: 10.1007/s10620-017-4732-6
|
4 |
Wânia Cristina da Silva, Vânia Eloisa de Araujo, Ellias Magalhães e Abreu Lima, Jessica Barreto Ribeiro dos Santos, Michael Ruberson Ribeiro da Silva, Paulo Henrique Ribeiro Fernandes Almeida, Francisco de Assis Acurcio, Brian Godman, Amanj Kurdi, Mariângela Leal Cherchiglia, Eli Iola Gurgel Andrade. Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. BioDrugs 2018; 32(6): 585 doi: 10.1007/s40259-018-0322-1
|
5 |
Jian Zhao, Jian Xu, Rui Zhang. MicroRNA‑539 inhibits colorectal cancer progression by directly targeting SOX4. Oncology Letters 2018; doi: 10.3892/ol.2018.8892
|
6 |
D. W. Siemann, D. J. Chaplin, M. R. Horsman. Realizing the Potential of Vascular Targeted Therapy: The Rationale for Combining Vascular Disrupting Agents and Anti-Angiogenic Agents to Treat Cancer. Cancer Investigation 2017; 35(8): 519 doi: 10.1080/07357907.2017.1364745
|
7 |
Ahmed El Kaffas, Assaf Hoogi, Jianhua Zhou, Isabelle Durot, Huaijun Wang, Jarrett Rosenberg, Albert Tseng, Hersh Sagreiya, Alireza Akhbardeh, Daniel L. Rubin, Aya Kamaya, Dimitre Hristov, Jürgen K. Willmann. Spatial Characterization of Tumor Perfusion Properties from 3D DCE-US Perfusion Maps are Early Predictors of Cancer Treatment Response. Scientific Reports 2020; 10(1) doi: 10.1038/s41598-020-63810-1
|
8 |
Giulia Dazio, Samantha Epistolio, Milo Frattini, Piercarlo Saletti. Recent and Future Strategies to Overcome Resistance to Targeted Therapies and Immunotherapies in Metastatic Colorectal Cancer. Journal of Clinical Medicine 2022; 11(24): 7523 doi: 10.3390/jcm11247523
|
9 |
Jasni Viralippurath Ashraf, Varun Sasidharan Nair, Reem Saleh, Eyad Elkord. Role of circular RNAs in colorectal tumor microenvironment. Biomedicine & Pharmacotherapy 2021; 137: 111351 doi: 10.1016/j.biopha.2021.111351
|
10 |
Xiaohua Zhong, Yipin Xiao, Chao Chen, Xiuwen Wei, Chen Hu, Xukun Ling, Xinbin Liu. MicroRNA-203-mediated posttranscriptional deregulation of CPEB4 contributes to colorectal cancer progression. Biochemical and Biophysical Research Communications 2015; 466(2): 206 doi: 10.1016/j.bbrc.2015.09.008
|
11 |
Yanfeng Gao, Shuang Zhou, Yi Xu, Sen Sheng, Steven Y. Qian, Xiongwei Huo. Nitric oxide synthase inhibitors 1400W and L-NIO inhibit angiogenesis pathway of colorectal cancer. Nitric Oxide 2019; 83: 33 doi: 10.1016/j.niox.2018.12.008
|
12 |
Vaishali Gupta, Taha Bharmal, Vineeta Dixit, Naveen Kumar Vishvakarma, Atul Kumar Tiwari, Dhananjay Shukla, Shirish Shukla. Colon Cancer Diagnosis and Therapy. 2021; : 219 doi: 10.1007/978-3-030-63369-1_11
|
13 |
Ana Vuletić, Katarina Mirjačić Martinović, Jelena Spasić. Role of Histone Deacetylase 6 and Histone Deacetylase 6 Inhibition in Colorectal Cancer. Pharmaceutics 2023; 16(1): 54 doi: 10.3390/pharmaceutics16010054
|
14 |
Alessia Bignucolo, Elena De Mattia, Erika Cecchin, Rossana Roncato, Giuseppe Toffoli. Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment. International Journal of Molecular Sciences 2017; 18(7): 1522 doi: 10.3390/ijms18071522
|
15 |
Jin Li, Ruihua Xu, Shukui Qin, Tianshu Liu, Hongming Pan, Jianming Xu, Feng Bi, Robert Lim, Suzhan Zhang, Yi Ba, Yuxian Bai, Nanfeng Fan, Akihito Tsuji, Kun-Huei Yeh, Brigette Ma, Vivian Wei, Dongmei Shi, Emmanuelle Magherini, Lin Shen. Aflibercept Plus Folfiri in Asian Patients with Pretreated Metastatic Colorectal Cancer: A Randomized Phase III Study. Future Oncology 2018; 14(20): 2031 doi: 10.2217/fon-2017-0669
|
16 |
Srila Gopal, Kenneth B. Miller, Iris Z. Jaffe. Molecular mechanisms for vascular complications of targeted cancer therapies. Clinical Science 2016; 130(20): 1763 doi: 10.1042/CS20160246
|
17 |
Tomoko Tachibana, Tomoko Gowa Oyama, Yukie Yoshii, Fukiko Hihara, Chika Igarashi, Mitsuhiro Shinada, Hiroki Matsumoto, Tatsuya Higashi, Toshihiko Kishimoto, Mitsumasa Taguchi. An In Vivo Dual-Observation Method to Monitor Tumor Mass and Tumor-Surface Blood Vessels for Developing Anti-Angiogenesis Agents against Submillimeter Tumors. International Journal of Molecular Sciences 2023; 24(24): 17234 doi: 10.3390/ijms242417234
|